Radiation sensitivity in prostate cancer patients

Not Applicable

Recruiting

• Conditions: Prostate Cancer; Cancer - Prostate

• Registration Number: ACTRN12605000538640
• Lead Sponsor: ROYAL ADELAIDE HOSPITA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-28
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 100

Inclusion Criteria

The first stage of the project is a case-control study involving 100 untreated Prostate cancer cases and 100 controls. Cases and controls will be matched for age, gender, familial history of cancer and smoking status.The second stage of the project is a prospective study aimed at determining whether the selected biomarkers predict abnormal tissue reaction in 100 localized Prostate cancer patients treated with RT who have ECOG 0-2 performance status and do not have a constant requirement for aperients or anti-diarrhoeal medication. Age, weight, tumour grade, family history of prostate cancer, use of anti-male hormone therapy and smoking status will be recorded.

Exclusion Criteria

No exclusion criteria

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. To determine whether increased in vitro sensitivity to radiation-induced DNA damage in lymphocytes is a predictor of prostate cancer risk.[];2. To develop a set of biomarkers that predict the risk of abnormal tissue reaction to radiotherapy in prostate cancer patients.[];3. To identify dietary and genetic factors that have a strong modifying effect on the risk of abnormal tissue reaction to radiotherapy.[]

Secondary Outcome Measures

Name	Time	Method
1. To determine whether increased in vitro sensitivity to radiation-induced DNA damage in lymphocytes is a predictor of prostate cancer risk.[];2. To develop a set of biomarkers that predict the risk of abnormal tissue reaction to radiotherapy in prostate cancer patients.[];3. To identify dietary and genetic factors that have a strong modifying effect on the risk of abnormal tissue reaction to radiotherapy.[]